Moderna says FDA wants extra time to finish evaluation of its COVID-19 shot for adolescents By Reuters


© Reuters. FILE PHOTO: An employee shows the Moderna COVID-19 vaccine at Northwell Health’s Long Island Jewish Valley Stream Hospital in New York, the United States, Dec. 21, 2020. REUTERS / Eduardo Munoz / File Photo

(Reuters) – Modern (NASDAQ 🙂 Inc said Sunday that it will take the U.S. Food and Drug Administration additional time to complete its assessment of the company’s COVID-19 vaccine for use in adolescents ages 12-17.

The FDA told Moderna that the review may not be completed before January 2022, the company said in a statement, implying a possible setback for the timing of an Emergency Authorization (EUA) for this age group.

Stephane Bancel, Chief Executive of Moderna, told Reuters last week -within-2021 -10-27 that, based on discussions with the agency, he believed that the vaccine would be approved for 12 to 17 year olds in the next few weeks.

The US biotech company said it was announced late Friday that the FDA would need the additional time to evaluate recent international analysis of the post-vaccination risk of developing a type of heart infection called myocarditis, a rare side effect that is primarily concerned young men.

Moderna said it will conduct its own review of new external analysis of the increased risk of myocarditis in those under the age of 18 as they become available.

Moderna applied for US approval of its inclusion for 12 to 17 year olds in June.

Americans of this age are eligible for the similar COVID-19 vaccine from Pfizer Inc (NYSE 🙂 and partner BioNTech SE (NASDAQ 🙂 after it was approved by the FDA and the Centers for Disease Control and Prevention in May.

Moderna also said it will delay filing its application for an EUA for a 50 microgram dose of the half strength vaccine for children ages 6-11 as the FDA completes its review of the 12-17 filing.

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price, meaning that prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.

Fusion Media or any other person involved in Fusion Media assumes no liability for any loss or damage that may arise from reliance on the information contained on this website, including data, prices, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment.

You might also like

Leave A Reply

Your email address will not be published.